Abstract

Parkinson's disease may be a disease of autointoxication. N-methylated pyridines (e.g. MPP+) are well-established dopaminergic toxins, and the xenobiotic enzyme nicotinamide N-methyltransferase (NNMT) can convert pyridines such as 4-phenylpyridine into MPP+, using S-adenosyl methionine (SAM) as the methyl donor. NNMT has recently been shown to be present in the human brain, a necessity for neurotoxicity, because charged compounds cannot cross the blood-brain barrier. Moreover, it is present in increased concentration in parkinsonian brain. This increase may be part genetic predisposition, and part induction, by excessive exposure to its substrates (particularly nicotinamide) or stress. Elevated enzymic activity would increase MPP+-like compounds such as N-methyl nicotinamide at the same time as decreasing intraneuronal nicotinamide, a neuroprotectant at several levels, creating multiple hits, because Complex 1 would be poisoned and be starved of its major substrate NADH. Developing xenobiotic enzyme inhibitors of NNMT for individuals, or dietary modification for the whole population, could be an important change in thinking on primary and secondary prevention.

Introduction

In 1887, a medical student in Strasbourg (W. His) gave a dog a quantity of the exogenous compound pyridine, and found it was predominantly excreted as its N-methyl derivative.1 Subsequent studies of xenobiotic metabolism and pharmacogenetics have yielded many examples of detoxification of foreign chemicals. Among such reactions, methyl conjugation is a well established pathway in the metabolism of endogenous agents, including hormones, neurotransmitters, vitamins and drugs. The xenobiotic metabolizing system must be an important defence mechanism, particularly as most xenobiotics are too small to be recognized by the immune system.

However, like the immune system, while normally protective, this system can also cause rather than prevent toxicity, by converting protoxins to toxins. In 1952, Peters coined the term ‘lethal synthesis from enzymic error', in his Croonian lecture to the Royal Society. He was referring to the neurotoxicity of fluoroacetic acid, a protoxin that crosses the blood brain barrier easily, and after conversion to fluorocitric acid impedes mitochondrial energy production due to blockade of the Krebs cycle,2 but many examples of this can be found from the conversion of prodrugs to drugs to toxic metabolites.

Here we suggest that the basis for idiopathic Parkinson's disease (PD) is a lethal synthesis from, with a failure to preserve, vitamin B3. There is evidence that genetic and environmental factors are important in this common disease,3–6 but until now, nobody has convincingly linked a specific gene with specified diet-derived substrates, let alone a vitamin. We propose a class of ecogenetic diseases of auto intoxication, and predict that chronic poisoning by transformed chemicals may be a common mechanism for conditions linked with ageing. Furthermore, we suggest that this hypothesis gives immediate ideas on primary prevention by dietary manipulation, reducing availability of the methyl donor, or the development of xenobiotic enzyme inhibitors (XEIs), a new class of therapeutic agents.

Nicotinamide N-methyltransferase (NNMT)

The enzyme that His was studying in 1887 was NNMT. This enzyme N-methylates pyridines, in particular nicotinamide to N-methyl nicotinamide, its major metabolite. (Figures 1 and 2). The remainder goes on to form NAD(H) and NADP(H), and therefore is vital to a large number of metabolic reactions. NADP(H) is generally associated with different roles from those of NAD(H),7 and is believed to serve primarily in oxidative defence or reductive metabolism.8 In the brain, a major oxidative defence mechanism consists of peroxide removal using GSH peroxidase. It has been demonstrated that GSH detoxification pathways may ultimately depend on the availability of NADPH reducing equivalents to replenish GSH as a cofactor for GSSG reductase. NAD(H), on the other hand, is believed to serve primarily in the energetic production of ATP. NAD+ depletion is considered a critical factor in precipitating cell death during oxidative stress due to compromised energetics. Of particular interest to PD, NADH is integral to: (i) the normal function of complex 1 of the mitochondrial chain (known to be defective in MPTP Parkinsonism9 and the idiopathic condition10,11); (ii) the formation of tetrahydrobiopterin (a co-factor for tyrosine hydroxylase and therefore important in the production of dopamine and known to be deficient in PD12) and reduced glutathione (also known to be deficient in early stages of PD13,14). Nicotinamide provides cytoprotection through pathways that involve poly (ADP-ribose) polymerase (PARP), Akt, mitochondrial membrane potential and cysteine protease activity. Nicotinamide also maintains cellular integrity and prevents cellular removal by maintaining DNA integrity and membrane phosphatidylserine (PS) asymmetry. It affects DNA degradation through a series of cellular pathways that involve PARP, Akt, forkhead transcription factor, mitochondrial membrane polarization, cytochrome c, and inhibition of caspase-1, caspase-3 and caspase-8. In addition, cellular membrane asymmetry, which prevents PS externalization and protects against microglial and cytokine activation with subsequent phagocytic destruction of cells, is maintained principally through activation of caspase-1 and caspase-8.15–26 Many of these pathways have been invoked for MPTP poisoning and PD.27–31 Nicotinamide protects against the toxic effects of L-DOPA in cell culture, as illustrated in Figure 3, and MPTP toxicity.32–3939 Experimental nicotinamide deficiency, produced by the antimetabolite 6-aminonicotinamide, causes dopamine deficiency, loss of cells in the pars compacta, and parkinsonism with a good response to dopamine agonists. Toxicity is based on the lethal synthesis of analogues of NADH and NADPH.40

Figure 1.

Formation of MPP+ from either MPTP by MAO-B, or methylation of 4-phenylpyridine by NNMT (top). Methylation of nicotinamide by NNMT (bottom).

Figure 1.

Formation of MPP+ from either MPTP by MAO-B, or methylation of 4-phenylpyridine by NNMT (top). Methylation of nicotinamide by NNMT (bottom).

Figure 2.

Pathways of synthesis of NADH, the essential cofactor for mitochondrial Complex 1, from nicotinamide, nicotinate and tryptophan. The enzymes involved in the nicotinamide pathway are listed below. Also shown schematically is the relationship between Complex 1 and Complex 5 of the mitochondrial oxidative phosphorylation pathway, the major source of ATP. The hypothesis proposed is that high levels of NNMT diminish the availability of nicotinamide for NADH synthesis at the same time that Complex 1 is inhibited, both resulting in diminished ATP synthesis. The tryptophan pathway occurs only to a very limited extent in brain, and therefore would not be able to compensate, and the nicotinate pathway would be affected by levels of NNMT because of the shuttling between NADH and nicotinamide. 1, purine-nucleoside phosphorylase [E.C. 2.4.2.1]; 2, nicotinamide ribonucleoside kinase [E.C. 2.7.1.22]; 3, nicotinamide mononucleotide adenylyltransferase [E.C. 2.7.7.1]; 4, NAD glycohydrolase (NADase CD38) [E.C. 3.2.2.5]; 5, nucleotide pyrophosphatase (Autotaxin) [E.C. 3.6.1.9]; 6, 5′ nucleotidase (CD73) [E.C. 3.1.3.5]. Alternative names shown in italics.

Figure 2.

Pathways of synthesis of NADH, the essential cofactor for mitochondrial Complex 1, from nicotinamide, nicotinate and tryptophan. The enzymes involved in the nicotinamide pathway are listed below. Also shown schematically is the relationship between Complex 1 and Complex 5 of the mitochondrial oxidative phosphorylation pathway, the major source of ATP. The hypothesis proposed is that high levels of NNMT diminish the availability of nicotinamide for NADH synthesis at the same time that Complex 1 is inhibited, both resulting in diminished ATP synthesis. The tryptophan pathway occurs only to a very limited extent in brain, and therefore would not be able to compensate, and the nicotinate pathway would be affected by levels of NNMT because of the shuttling between NADH and nicotinamide. 1, purine-nucleoside phosphorylase [E.C. 2.4.2.1]; 2, nicotinamide ribonucleoside kinase [E.C. 2.7.1.22]; 3, nicotinamide mononucleotide adenylyltransferase [E.C. 2.7.7.1]; 4, NAD glycohydrolase (NADase CD38) [E.C. 3.2.2.5]; 5, nucleotide pyrophosphatase (Autotaxin) [E.C. 3.6.1.9]; 6, 5′ nucleotidase (CD73) [E.C. 3.1.3.5]. Alternative names shown in italics.

Figure 3.

Nicotinamide protection against the cytotoxic effects of L-DOPA. TE671 cells exposed to increasing concentrations of L-DOPA for 24 h in the presence or absence of 0.1 mM nicotinamide. Cytotoxicity determined by assay of LDH release. Nicotinamide produced a statistically significant reduction in cytotoxicity across the range of L-DOPA concentration (p<0.0001). Results previously presented in abstract form (Cartwright L, Williams AC, Ramsden DB. Nicotinamide: neuroprotective effects against dopamine and MPP+. Proceedings of The Global College of Neuroprotection and Neuroregeneration, Annual Conference 2004, Zermatt).

Figure 3.

Nicotinamide protection against the cytotoxic effects of L-DOPA. TE671 cells exposed to increasing concentrations of L-DOPA for 24 h in the presence or absence of 0.1 mM nicotinamide. Cytotoxicity determined by assay of LDH release. Nicotinamide produced a statistically significant reduction in cytotoxicity across the range of L-DOPA concentration (p<0.0001). Results previously presented in abstract form (Cartwright L, Williams AC, Ramsden DB. Nicotinamide: neuroprotective effects against dopamine and MPP+. Proceedings of The Global College of Neuroprotection and Neuroregeneration, Annual Conference 2004, Zermatt).

Increased activity of NNMT therefore would lead to cellular nicotinamide deficiency with complex results, as seen clinically in pellagra, but with reasons to believe damage would occur to dopaminergic systems, and to the cells ability to withstand an attack from dopaminergic toxins such as MPP+ and therapy with Levodopa. The latter, when combined with a decarboxylase inhibitor (vitamin B6 antagonists) will reduce the amount of nicotinamide reaching cells. Given that NNMT is partly under genetic control, there may be an evolutionary hunter/gatherer style link between the gene and a particular environment that is high in nicotinamide, as would happen with an omnivorous or carnivorous diet (NNMT barely exists in herbivores).41 This may provide some homeostatic control, but would not necessarily avoid long-latency toxicity. NNMT has been cloned, and its structure is known.42–44 It may possibly be polymorphic, but the structural basis of the polymorphism or duplications is unknown, and does not appear to be within the coding region of the gene. Alternatively the genetic control may be post-translational. The protein is inducible by its own substrates, and by other factors, including stress. Twenty-five per cent of the general population are high expressors of NNMT.

Toxicity of N-methyl compounds

A single case45 followed by a small epidemic of parkinsonism46 in young heroin injectors was found to be caused by MPTP, a N-methylated pyridine. The similarity with idiopathic PD is striking at the clinical, pathological and biochemical levels and has led to excellent animal models. Most of the biochemical and physiological abnormalities found in the last 20 years from the deficit of complex 1 and the involvement of the subthalamic nucleus in PD were first discovered in the MPTP model, and it has been extensively used for drug and surgical developments. It was soon found that compounds of similar structure that did not have the N-methyl moiety were not toxic to any degree.47,48 MPTP is a protoxin converted by MAO-B to MPP+.49 MPP+ and similarly charged compounds cannot cross the blood brain barrier. If this conversion occurs within the brain, MPP+ may be taken up into dopaminergic cells and concentrated via the dopamine active transport system and further concentrated in mitochondria where it poisons complex 1.50,51 Inhibition of MAO-B prevents MPTP toxicity, which is also relatively less toxic by the oral route because MAO-B in liver converts it to MPP+, which then cannot cross the blood-brain barrier. Interestingly, inhibition of MAO-B does not affect the natural history of Parkinson's disease. However, an alternative and direct pathway converts pyridines, including nicotinamide and 4-phenyl pyridine, directly to MPP+ and similar compounds This route is catalysed by NNMT (Figure 1).52 If this happened in vivo, MAO-B inhibition would not obviate the generation of toxins. Several N-methylated compounds and/or their N-methylating enzymes (probably NNMT) have been proposed as being involved in Parkinson's disease.53–64 However these findings have not been generally accepted, in part because it was unclear whether the relevant enzyme occurred in the CNS of mammals.65

Nicotinamide metabolism in parkinsonian patients

An initial study in Man66–69 followed the Wilhelm His protocol in dogs, and demonstrated that patients with Parkinson's disease excreted high quantities of N-methyl nicotinamide, compared with controls or patients with other neurodegenerative disease.70 However, at the time, the brain was not thought to contain NNMT, and therefore there were problems with the hypothesis, because increased methylation peripherally would reduce available nicotinamide but the charged N-methyl compounds would not cross the blood-brain barrier.71 However, NNMT is found in the brain, and indeed is within neurones including dopaminergic neurones of the substantia nigra (Figure 4).72 It has a regional distribution, presumably reflecting nicotinamide requirements.73 Low nicotinamide levels are toxic, but so are high levels,74,75 so tight control may be necessary. Intra-neuronal nicotinamide levels may be a link between degeneration when too low, and carcinogenesis or developmental problems when too high via PARP depletion,76 such as might be achieved by high dietary intake of nicotinamide and low methylator status from genetic pre-disposition plus an inhibitor of NNMT such as nicotine. N-methylnicotinamide may have acquired a normally beneficial role as it inhibits the export of choline77 (also a charged N-methylated compound) from the brain, and therefore boosts acetylcholine levels. This may help developing cognition, and even delay the effects of cholinergic degeneration although it would not be pharmacologically helpful in patients who already had PD. On the other hand, N-methyl nicotinamide has MPP+-like toxicity,78–80 and choline as a methyl donor would facilitate further methylation. NNMT levels are high in the spinal cord and in some parts of the cortex, suggesting that such regions prefer lower nicotinamide and higher N-methyl nicotinamide, and vice versa for regions such as substantia nigra with low levels of the enzyme. In Parkinson's disease brain, levels of this enzyme are high (Figure 5).73,81,82 They were not raised in the substantia nigra, but as a neuronal protein, the destruction from the disease process makes this hardly surprising; levels might have been high before the destruction took place. In any case, N-methyl compounds could diffuse from other parts of the brain and get taken up by dopaminergic cells, as happens with MPTP poisoning.

Figure 4.

A Fluorescent microscopy of control human substantia nigra with FITC-labelled anti-NNMT, showing presence of NNMT in dopaminergic neurones (cell bodies and projections). B Conventional microscopy of control human cerebellum. Section stained with anti-NNMT and peroxidase-conjugated second antibody. Brown indicates presence of NNMT; blue is due to counterstain. Light positive (brown) staining indicates low levels of NNMT in granular layer neurones. C Conventional microscopy of parkinsonian human cerebellum. Section stained with anti-NNMT and peroxidase-conjugated second antibody. Brown indicates presence of NNMT; blue is due to counterstain. Heavy positive (brown) staining indicates high levels of NNMT in granular layer neurones. D, EIn situ hybridization with control human cerebellum, using antisense NNMT probe. Low levels of NNMT mRNA evidenced by low levels of bright purple staining. E shows Purkinje cells in addition to granular layer neurones. FIn situ hybridization with parkinsonian human cerebellum using antisense NNMT probe. High level of NNMT mRNA evidenced by high levels of bright purple staining.

Figure 4.

A Fluorescent microscopy of control human substantia nigra with FITC-labelled anti-NNMT, showing presence of NNMT in dopaminergic neurones (cell bodies and projections). B Conventional microscopy of control human cerebellum. Section stained with anti-NNMT and peroxidase-conjugated second antibody. Brown indicates presence of NNMT; blue is due to counterstain. Light positive (brown) staining indicates low levels of NNMT in granular layer neurones. C Conventional microscopy of parkinsonian human cerebellum. Section stained with anti-NNMT and peroxidase-conjugated second antibody. Brown indicates presence of NNMT; blue is due to counterstain. Heavy positive (brown) staining indicates high levels of NNMT in granular layer neurones. D, EIn situ hybridization with control human cerebellum, using antisense NNMT probe. Low levels of NNMT mRNA evidenced by low levels of bright purple staining. E shows Purkinje cells in addition to granular layer neurones. FIn situ hybridization with parkinsonian human cerebellum using antisense NNMT probe. High level of NNMT mRNA evidenced by high levels of bright purple staining.

Figure 5.

NNMT expression in cerebellar granular layer neurones. A Frequency of control subjects with low, intermediate or high expression. B Frequency of parkinsonian subjects with low, intermediate or high expression. C Comparison of expression in control and parkinsonian subjects; means are shown as solid symbols. Reprinted from Neuroscience Letters, Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB, High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease, 342:13–16, 2003, with permission from Elsevier.

Figure 5.

NNMT expression in cerebellar granular layer neurones. A Frequency of control subjects with low, intermediate or high expression. B Frequency of parkinsonian subjects with low, intermediate or high expression. C Comparison of expression in control and parkinsonian subjects; means are shown as solid symbols. Reprinted from Neuroscience Letters, Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB, High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease, 342:13–16, 2003, with permission from Elsevier.

S-adenosyl methionine (SAM)

SAM is the methyl donor for this and most other important methylation reactions, including that of DNA and RNA. One study showed decreased CSF levels in untreated Parkinson's disease,83 and this was lowered further by treatment.84 The former is presumably due to increased consumption perhaps from N-methylation and the latter from methylation of dopamine by catechol-O-methyl transferase (COMT). Forcing dopamine catabolism down the methylation path by blocking decarboxylation and MAO-B, particularly in patients with the high methylator COMT polymorphism, would consume SAM, reducing the amount available for other methylation reactions. This may explain some of the beneficial effects of Levodopa, which have always been complex and on several timescales not necessarily all explained by dopamine replacement. Nor are side-effects such as dyskinesia fully explained, and it is possible that a de-methylation/re-methylation injury is to blame, which is the reason given when infants who are vitamin-B12-deficient and are treated with this indirect methyl donor develop dyskinesia. Blocking COMT using inhibitors now widely available may therefore have unforeseen consequences, by boosting SAM, which can cross the blood-brain barrier. This is particularly true for Tolcapone, which unlike Entacapone inhibits COMT centrally, and therefore would increase SAM directly in the brain.85,86 This central effect might explain its better immediate symptomatic response, but may cause longer-term toxicity. Arguing strongly for the methylation hypothesis, increasing SAM in striatum in animal models causes MPP+-like toxicity.87 Trials comparing disease progression with SAM-reducing, SAM-neutral and SAM-increasing strategies would be of interest. Agents that reduce its synthesis from methionine or increase its consumption or catabolism toward cysteine might need to be developed.

Known environmental risk factors

Would this fit with the other known risk factors for Parkinson's disease? Age is the greatest risk factor, and slow poisoning is therefore an attractive mechanism. There may be some brakes on the age increase, or it would be exponential, e.g. NNMT activity may decline with age.70 The strongest environmental factors are nicotine and caffeine, which are both protective.88–95 No convincing mechanism for this has been described, but both are N-methylated compounds, which seems an extraordinary coincidence (Figure 6). As Paracelsus first predicted, causes and cures may be closely related structurally. Nicotine is already N-methylated but has another potential site, and is a substrate (and therefore may act as a inhibitor) of NNMT. Caffeine is already N-methylated at three sites, but given that demethylation is its normal catabolic event, it may get re-methylated by NNMT and also then act as a substrate, or it may be an inhibitor in its own right.

Figure 6.

Structural formulae of nicotine and caffeine.

Figure 6.

Structural formulae of nicotine and caffeine.

Studies on dietary nicotinamide intake in Parkinson's are confusing.96,97 It has been proposed that high nicotinamide in diet is protective, but this has been disputed and is confounded by the fact that coffee has a high nicotinamide component. Parkinson's disease is rare in alcoholics who are at risk of nicotinamide deficiency. Pellagra is commoner in women, probably because oestrogen suppresses tryptophan metabolism, which is an important source of NADH in liver. Also, their dietary intake of nicotinamide is lower than in men.98 Parkinson's disease, on the other hand, is commoner in men.97 Parkinson's disease is also rare in regions such as Africa where pellagra still occurs, even though Black Americans get PD at the same rate as White Americans within a few generations.99 The epidemiological data on nicotinamide dietary dose is therefore conflicting, and could fit with a ratio of pyridine intake that is skewed toward protoxic rather than protectant compounds. At an individual level, any safe intake may well differ between high and low methylators, and there may be a window with toxicity at the extremes. Thus the epidemiology may not be explicable until we can either phenotype or genotype patients at the same time as making a complex assessment of dietary intake of most of the relevant compounds. Clearly, high methylators may need less protoxin to cause damage. They also may prove to have different smoking or coffee-drinking habits, as the increased methylation may be either unpleasant and lead to avoidance, or need a higher dose to get the pleasant and addictive effects. Indeed, the interaction between nicotine and NNMT should be investigated separately to understand its role in addiction.

Genetic risk factors

There has been immense recent interest in the genetics of the rare Mendelian versions of Parkinson's disease. These discoveries have highlighted the role of proteins such as α-synuclein, Parkin, UCHL1, DJ1 and PINK 1.100–107 The mechanism in these families is not known, but the lead hypothesis is that they interfere with the ubiquitin-proteasome pathway, or with other components of cellular protective mechanisms, including Complex 1 and free radical defence mechanism pathways that had already been implicated in Parkinson's disease. Ubiquitination is important in the removal of already damaged proteins, and is ATP-dependent, so could be impaired secondary to energy failure or as a primary event in these families. What has not been explained is what threatens the cell in the first place. Even in these families, a MPP+ like compound could be the trigger, although needing a lower dose of toxin than in idiopathic Parkinson's disease, perhaps explaining their earlier onset of clinical disease. Certainly α-synuclein knockout mice are resistant to MPP+,108,109 and inhibition of Complex 1 makes cells sensitive to MPP+,110,111 as are models of PARKIN mutations;112 one would predict the same with DJ1 and PINK 1 equivalents.113 Toxic exposure can cause upregulation of α-synuclein.114 Cause and effect can easily get confused here, and potential feedback loops from a network of biochemical changes may well be present, emphasizing the need to move proximally for the greatest chance of successful therapeutic intervention. Parkinson's disease may have a myriad of rare causes and common risk and protective factors, but they may all be affecting a single pathway. The methylation hypothesis is inclusive, in that N-methylation may be at the head of a toxico-biochemical pathway that later includes these proteins and mechanisms of cell death.

Conclusion

Hypersusceptibility to chemicals may be a cause of degenerative disease such as Parkinson's disease, and may be happening at the xenobiotic enzyme level.115–117 Both high exposure to protoxic pyridines relative to protectant compounds, and genetic predisposition in the form of high N-methylating capacity, are necessary to cause disease. Consequently, most patients will not have a family history. We suggest that a toxic brew of a variety of N-methyl compounds is a likely scenario, defining at least at first the selective death of dopaminergic neurones. Details of the mix would vary between different individuals, depending on the degree and nature of the exposure. This may explain phenotypic variation, including toxicity outside traditional MPP+ territory, as some of the toxins may not be so selective.118 A logical strategy would be either to reduce environmental exposure to protoxin or to increase exposure to protectants, either in the whole population or in individuals at risk. However, that may not be simple, as a glance at Figure 2 demonstrates. The case of nicotinamide-NNMT is an example of a two-edged sword, because cells may benefit from more of the protectant, nicotinamide, but be damaged by increased levels of toxic N-methylnicotinamide.

High exposure to its substrates, particularly nicotinamide to which the Western population has become increasingly exposed may induce the enzyme, as will stress. This could be the first of several increasingly toxic vicious circles that result from the intra-neuronal deficiency of the vitamin or its downstream direct and indirect products, such as NADH and ATP combined with toxicity from several N-methylated compounds. If true, we are dealing with upstream events and switching them off would not just affect one part of a late cascade of biochemical events or be purely symptomatic, or be only aimed at the dopaminergic damage. Increased irreversible catabolism of nicotinamide may lead to the cellular deficiency of the vitamin and of products, which would also affect non-dopaminergic cells as seen in pellagra. Here dementia and depression are the predominant features, but autonomic, pontine, anosmic and sleep disturbances are seen, and remarkably, also parkinsonism in 10–20% of cases.119 One nicotinamide anti-metabolite, 3-acetyl pyridine, causes atypical parkinsonism, and has been suggested as a model of olivopontocerebellar atrophy.120 In view of the fact that dementia and some of these other atypical features of Parkinson's disease occur in these circumstances, one wonders whether the clinical pathological spectrum of parkinsonism, and not just classic Parkinson's disease, is a hybrid of pyridinium ion poisoning and pellagra.

Altering nicotinamide in the diet as a potential protective manoeuvre may work, but the dose may need to be individualized, and N-methyl compounds would still be produced, including N-methylated nicotinamide. Western societies who suffer more from PD may now have too much nicotinamide in their diet overall, and this may need to be addressed at the population level. Strategies to reduce methylation by removing the co-factor SAM using existing drugs or the development of SAM-depleting agents would be a novel avenue to explore, but would affect other necessary methylation reactions. Inhibition of the enzyme NNMT may be more incisive, as it would boost intracellular nicotinamide and reduce or stop the production of any N-methyl compounds. If the enzyme has been induced over a lifetime by excessive exposure to its substrates or other factors, a reduction in such stimuli may not reverse its overactivity quickly or completely. Competitive inhibitors could be developed, because they are often structurally related to the known substrates. Two lead compounds that may be protective are nicotine and caffeine. Neither may be practical, because they have their own toxicity. Nevertheless, they, along with the structures of nicotinamide or 4-phenyl pyridine may provide clues to the development of a safe pyridine, whether natural or synthetic, leading to attempts at primary and secondary prevention based on a strong hypothesis supported by both biochemical and epidemiological evidence. Symptomatic therapies have obvious limitations, but so does targeting downstream biochemical events, as has been learnt, often painfully, from cancer and inflammatory diseases. XEIs alone or dietary or SAM manipulation may prove to be a revolutionary new class of preventive therapeutic agents, not just for Parkinson's disease. One example of such a possibility is overactive xenobiotic sulphur methylation pathway, which has been implicated in motor neurone disease.121,122 Given that metal123 or pesticide exposure124,125 may be a risk factor for MND, and S-methylation of some compounds increases their toxicity, a very similar ecogenetic scenario can be postulated. MPTP was discovered by a freak event in drug users; MND may never have had the equivalent lucky break. One can make similar arguments for some other diseases, including cancer and processes linked with increasing age. Indeed, more varied diets may inadvertently reduce xenobiotic load, perhaps explaining the recent increase in longevity not wholly due to improvements in healthcare. Dietary restriction has long been known to increase life-span and reduce age related disease in experimental animals, and is attributed to lower caloric intake,126 but might also be related to lower daily xenobiotic exposure.

References

1
His W. Ueber das Stoffwechsel-product des Pyridins.
Arch Exp Pathol Pharmakol
 
1887
;
22
:
253
–60.
2
Peters RA. Lethal synthesis.
Proc R Soc Lond (Biol)
 
1952
;
139
:
10
–170.
3
Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study.
JAMA
 
1999
;
281
:
376
–8.
4
Vieregge P, Hagenah J, Heberlein I, Klein C, Ludin HP. Parkinson's disease in twins: a follow-up study.
Neurology
 
1999
;
53
:
566
–72.
5
Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins.
Ann Neurol
 
1999
;
45
:
577
–82.
6
Di Monte D. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?
Lancet Neurol
 
2003
;
2
:
531
–6.
7
Maise K, Chong ZZ. Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain.
Trends Pharmacol Sci
 
2003
;
24
:
228
–30.
8
Klaidman LK, Mukherjee SK, Adams JD Jr. Oxidative changes in brain pyridine nucleotides and neuroprotection using nicotinamide.
Biochim Biophys Acta
 
2001
;
1525
:
136
–48.
9
Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Life Sci
 
1985
;
36
:
2503
–8.
10
Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease.
Biochem Biophys Res Commun
 
1989
;
163
:
1450
–5.
11
Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease.
J Neurochem
 
1990
;
55
:
2142
–5.
12
Lovenberg W, Levine RA, Robinson DS, Ebert M, Williams AC, Calne DB. Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease.
Science
 
1978
;
204
:
624
–6.
13
Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?
Neurosci Lett
 
1982
;
33
:
305
–10.
14
Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease.
Neurosci Lett
 
1992
;
142
:
128
–30.
15
Lin SH, Chong ZZ, Maiese K. Nicotinamide: a nutritional supplement that provides protection against neuronal and vascular injury.
J Med Food
 
2001
;
4
:
27
–38
16
Maynard KI, Ayoub IA, Shen CC. Delayed multidose treatment with nicotinamide extends the degree and duration of neuroprotection by reducing infarction and improving behavioral scores up to two weeks following transient focal cerebral ischemia in Wistar rats.
Ann NY Acad Sci
 
2001
;
939
:
416
–24.
17
Lin SH, Vincent A, Shaw T, Maynard KI, Maiese K. Prevention of nitric oxide-induced neuronal injury through the modulation of independent pathways of programmed cell death.
J Cereb Blood Flow Metab
 
2000
;
20
:
1380
–91.
18
Mokudai T, Ayoub IA, Sakakibara Y, Lee EJ, Ogilvy CS, Maynard KI. Delayed treatment with nicotinamide (vitamin B3) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats.
Stroke
 
2000
;
31
:
1679
–85.
19
Yang J, Klaidman LK, Chang ML, Kem S, Sugawara T, Chan P, Adams JD. Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model.
Pharmacol Biochem Behav
 
2002
;
73
:
901
.
20
Dombroski D, Balasubramanian K, Schroit AJ. Phosphatidylserine expression on cell surfaces promotes antibody-dependent aggregation and thrombosis in beta2-glycoprotein I-immune mice.
J Autoimmun
 
2000
;
14
:
221
–9.
21
Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines.
Clin Exp Immunol
 
2003
;
131
:
48
–52.
22
Kops GJ, Dansen TB, Polderman PE, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress.
Nature
 
2002
;
419
:
316
–21.
23
Lemeshko SV, Lemeshko VV. Metabolically derived potential on the outer membrane of mitochondria: a computational model.
Biophys J
 
2000
;
79
:
2785
–800.
24
Southan GJ, Szabo C. Poly(ADP-ribose) polymerase inhibitors.
Curr Med Chem.
 
2003
;
10
:
321
–40.
25
Yang J, Klaidman LK, Nalbandian A, et al. The effects of nicotinamide on energy metabolism following transient focal cerebral ischemia in Wistar rats.
Neurosci Lett
 
2002
;
333
:
91
–4.
26
Ying W, Sevigny MB, Chen Y, Swanson RA. Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death.
Proc Natl Acad Sci USA
 
2001
;
98
:
12227
–32.
27
Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease.
Exp Neurol
 
2000
;
166
:
29
–43.
28
Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?
Ann Neurol
 
1998
;
44(suppl 1.)
:
S115
–20.
29
Bolanos JP, Almeida A, Stewart V, et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases.
J Neurochem
 
1997
;
68
:
2227
–40.
30
Kosel S, Egensperger R, von Eitzen U, et al. On the question of apoptosis in the Parkinsonian substantia nigra.
Acta Neuropathol (Berl)
 
1997
;
93
:
105
–8.
31
Beal F. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis.
Ann Neurol
 
1998
;
44
:
110
–14.
32
Kiuchi K, Yoshizawa K, Shikata N, Matsumura M, Tsubura A. Nicotinamide prevents N-methyl-N-nitrosourea-induced photoreceptor cell apoptosis in Sprague-Dawley rats and C57BL mice.
Exp Eye Res
 
2002
;
74
:
383
–92.
33
Mandir AS, Przedborski S, Jackson-Lewis V, et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism.
Proc Natl Acad Sci USA
 
1999
;
96
:
5774
–9.
34
Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease.
Annals of Neurology
 
2003
;
53(Suppl. 3)
:
39
–47.
35
Crowley CL, Payne CM, Bernstein H, Bernstein C, Roe D. The NAD+ precursors, nicotinic acid and nicotinamide protect cells against apoptosis induced by a multiple stress inducer, deoxycholate.
Cell Death Differ
 
2000
;
7
:
314
–26.
36
Cosi C, Colpaert F, Koek W, et al. Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice.
Brain Res
 
1996
;
729
:
264
–9.
37
Schultz JB, Henshaw DR, Matthews RT, Beal MF. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity.
Exp Neurol
 
1995
;
132
:
279
–83.
38
Mandir AS, Przedborski S, Jackson-Lewis V, et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism.
Proc Natl Acad Sci USA
 
1999
;
96
:
5774
–9.
39
Cosi C, Marien M. Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide.
Brain Res
 
1998
;
809
:
58
–67.
40
Loos D, Halbhubner K, Kehr W, Herken H. Action of dopamine antagonists on Parkinson-like muscle rigidity induced by 6-aminonicotinamide.
Neuroscience
 
1979
;
4
:
667
–76.
41
Alston TA, Abeles RH. Substrate specificity of Nicotinamide methyl transferase isolated from porcine liver.
Arch Biochem Biophys
 
1988
;
260
:
601
–8.
42
Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase.
Ann Rev Pharmacol Toxicol
 
1999
;
39
:
19
–52.
43
Smith M-L, Burnett D, Bennett P, et al. A direct correlation between nicotinamide N-methyltransferase activity and protein levels in the human liver cytosol.
Biochem Biophys Acta
 
1998
;
1422
:
238
–44.
44
Rini J, Szumlanski C, Guerciolini R, Weinshilboum RM. Human liver nicotinamide N-methyltransferase: ion-pairing radiochemical assay, biochemical properties and individual variation.
Clinica Chimica Acta
 
1990
;
186
:
359
–74.
45
Davies GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues.
Psychiatr Res
 
1979
;
1
:
249
–54.
46
Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis.
Science
 
1983
;
219
:
979
–80.
47
Bradbury AJ, Costall B, Domeney AM, et al. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking the N-methyl moiety.
Neurosci Lett
 
1985
;
61
:
121
–6.
48
Athwall NS, Ramsden DB, Simpson M, Williams AC. Inhibition of dopamine uptake into PC-12 cells by analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Parkinsonism Related Disorders
 
1996
;
2
:
1
–6.
49
Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.
Biochem Biophys Res Commun
 
1984
;
120
:
574
–8.
50
Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
Proc Natl Acad Sci USA
 
1985
;
82
:
2173
–7.
51
Ramsey RR, Singer TP. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria.
J Biol Chem
 
1986
;
261
:
7585
–7.
52
Ansher SS, Cadet JL, Jakoby WB, Baker JK. Role of N-methyl-transferases in the neurotoxicity associated with the metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and other 4-substituted pyridines in the environment.
Biochem Pharmacol
 
1986
;
35
:
3359
–63.
53
Collins MA, Neafsey EJ, Matsubara K, Cobuzzi RJ Jr, Rollema H. Indole-N-methylated beta-carbolinium ions as potential brain-bioactivated neurotoxins.
Brain Res
 
1992
;
570
:
154
–60.
54
Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF.
J Neurochem
 
1995
;
65
:
2633
–8.
55
Maruyama Y, Abe T, Tohgi H, Dostert P, Naoi M. A dopaminergic neurotoxin, (R)- N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid.
Ann Neurol
 
1996
;
40
:
119
–22.
56
Matsubara K, Kobayashi S, Kobayashi Y, et al. β-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of parkinsonian patients.
Neurology
 
1995
;
45
:
2240
–5.
57
Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease.
Neurosci Res
 
1997
;
29
:
99
–111.
58
Nagatsu T, Yoshida M. An endogenous substrate of brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostratal regions.
Neurosci Lett
 
1988
;
87
:
178
–82.
59
Naoi M, Matsuura S, Takahashi T, Nagatsu T. A N-methyl-transferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion.
Biochem Biophys Res Commun
 
1989
;
161
:
1213
–19.
60
Naoi M, Dostert P, Yoshida M, Nagatsu T. N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins.
Adv Neurol
 
1993
;
60
:
212
–17.
61
Naoi M, Maruyama W, Niwa T, Nagatsu T. Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin.
J Neural Transm
 
1994
;
41(Suppl.)
:
197
–205.
62
Naoi M, Maruyama W, Nakao N, Ibi T, Sahashi K, Benedetti MS. (R) Salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes.
Ann Neurol
 
1998
;
43
:
212
–16.
63
Akoyama K, Matsubara K, Kondo M, et al. Nicotinamide N-methyl-transferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease.
Neurosci. Lett
 
2001
;
298
:
78
–80.
64
Gearhart DA, Collins MA, Lee JM, Neafsey EJ. Increased beta-carboline N-methyltransferase activity in the frontal cortex in Parkinson's disease.
Neurobiol Dis
 
2000
;
7
:
201
–11.
65
Gerlach M, Koutsilieri E, Riederer P. N-methyl-(R)-salsolinol and its relevance to Parkinson's disease.
Lancet
 
1998
;
351
:
850
–1.
66
Green S, Buttrum S, Molloy H, et al. N-methylation of pyridines in Parkinson's disease.
Lancet
 
1991
;
338
:
120
–1.
67
Williams A, Sturman S, Steventon G, Waring R. Metabolic biomarkers of Parkinson's disease.
Acta Neurol Scand
 
1991
;
84(Suppl 136)
:
19
–23.
68
Williams AC, Pall HS, Steventon GB, Green S, Buttrum S, Molloy H, Waring RH. N-methylation of pyridines and Parkinson's disease.
Adv Neurol
 
1993
;
60
:
194
–6.
69
Williams AC, Waring RH. The MPTP tale: pathway to prevention of Parkinson's disease?
Br J Hosp Med
 
1993
;
49
:
716
–19.
70
Akoyama K, Matsubara K, Okada K, et al. N-Methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test.
J Neural Transm
 
2000
;
107
:
985
–95.
71
Spector R. Niacin and niacinamide transport in the central nervous system. In vivo studies.
J Neurochem
 
1979
;
33
:
895
–904.
72
Williams AC, Smith M-L, Waring RH, Ramsden DB. The aetiology of idiopathic Parkinson's disease: a genetic and environmental model.
Adv. Neurol
 
1999
;
80
:
215
–18.
73
Ramsden DB, Parsons RB, Ho S-L, Xie T, Waring RH, Williams AC. Further studies in Xenobiotic Metabolism and Parkinson's disease.
Adv Neurol
 
2001
;
86
:
105
–13.
74
Hervias I, Lasheras B, Aguirre N. 2-deoxy-D-glucose prevents and nicotinamide potentiates 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity.
J Neurochem
 
2000
;
75
:
982
–90.
75
Chong ZZ, Lin SH, Maiese K. Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury.
J Vasc Res
 
2002
;
39
:
131
–47.
76
Hageman GJ, Stierum RH. Niacin, poly(ADP-ribose) polymerase-1 and genomic stability.
Mutat Res
 
2001
;
475
:
45
–56.
77
Vargas HM, Jenden DJ. Elevation of cerebralspinal fluid choline levels by nicotinamide involves the enzymatic formation of N-methylnicotinamide in brain tissue.
Life Sci
 
1996
;
58
:
1995
–2002.
78
Willets J, Lunec J, Williams AC, Griffiths HR. Neurotoxicity of nicotinamide derivatives; their role in the aetiology of Parkinson's disease.
Biochemical Society Transactions
 
1993
;
21
:
299S
.
79
Fukushima T, Tawara T, Isobe A, Hojo N, Shiwaku K, Yumane Y. Radical formation site of cerebral complex 1 and Parkinson's disease.
Journal of Neuroscience Research
 
1995
;
42
:
385
–90.
80
Fukushima T, Kaetsu A, Lim H, Moriyama M. Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease.
Exp Toxic Pathol
 
2002
;
53
:
469
–73.
81
Parsons RB, Smith M-L, Williams AC, Waring RH, Ramsden DB. Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain.
J Neuropathol Exp Neurol
 
2002
;
61
:
111
–24.
82
Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB. High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease.
Neurosci. Lett
 
2003
;
342
:
13
–16.
83
Pall HS, Surtees R, Sturman SG, Powell A, Williams AC. S-adenosylmethionine in cerebrospinal fluid in Parkinson's disease.
Neurology
 
1992
;
42(Suppl. 3)
:
283
.
84
Müller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease.
Neurosci. Lett
 
2001
;
308
:
54
–6.
85
Kuhn W, Woitalla D, Gerlach M, Russ H, Müller T. Tolcapone and neurotoxicity in Parkinson's disease.
Lancet
 
1998
;
352
:
1313
–14.
86
Da Prada M, Borgulya J, Napolitano A, et al. Improved therapy of Parkinson's disease with Tolcapone, a central and peripheral COMT Inhibitor with an S-Adenosyl-L-Methionine-sparing effect.
Clin Neuropharmacol
 
1994
;
17(Suppl. 3)
:
S26
–37.
87
Charlton CG, Crowell B Jr. Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine: a possible role of hypermethylation in Parkinsonism.
Mol Chem Neuropathol
 
1995
;
26
:
269
–83.
88
Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease.
JAMA
 
2000
;
283
:
2674
–9.
89
Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.
Ann Neurol
 
2001
;
50
:
56
–63.
90
Sugita M, Izuno T, Tatemichi M, Otahara Y. Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson's disease.
J Epidemiol
 
2001
;
11
:
87
–94.
91
Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?
Neurology
 
1995
;
45
:
1041
–51.
92
Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson's disease: a dose-response relationship.
Neurology
 
1999
;
52
:
115
–19.
93
Tanner CM, Goldman SM, Aston DA, et al. Smoking and Parkinson's disease in twins.
Neurology
 
2002
;
58
:
581
–8.
94
Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease.
JAMA
 
2000
;
283
:
2674
–9.
95
Benedetti MD, Bower JH, Maraganore DM, et al. Smoking, alcohol, and coffee consumption preceeding Parkinson's disease: a case-control study.
Neurology
 
2000
;
55
:
1350
–8.
96
Hellenbrand W, Boeing H, Robra B-P, et al. Diet and Parkinson's disease II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study.
Neurology
 
1996
;
47
:
644
–50.
97
Fall, P-A, Fredrikson M, Axelson O, Granérus A-K. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden.
Movement Disorders
 
1999
;
14
:
28
–37.
98
Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging.
Neurology
 
2000
;
55
:
1358
–63.
99
Zhang Z-H, Román GC. Worldwide occurance of Parkinson's disease: an updated review.
Neuroepidemiology
 
1993
;
12
:
195
–208.
100
Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease.
Science
 
1997
;
276
:
2045
–7.
101
Tan EK, Tan C, Shen H, et al. Alpha synuclein promoter and risk of Parkinson's disease: smicrosatellite and allelic size variability.
Neurosci Lett
 
2003
;
336
:
70
–2.
102
Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
Nature
 
1998
;
392
:
605
–8.
103
Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease.
Neurology
 
1999
;
53
:
1858
–60.
104
Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease.
Nature
 
1998
;
395
:
451
–2.
105
Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
Science
 
2003
;
299
:
256
–9.
106
Hardy J, Cookson MR, Singleton A. Genes and parkinsonism.
Lancet Neurol
 
2003
;
2
:
221
–8.
107
Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary Early-Onset Parkinson's Disease Caused by mutations in PINK1.
Science
 
2004
;
304
:
1158
–60.
108
Dauer W, Kholodilov N, Vila M, et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP.
Proc Natl Acad Sci USA
 
2002
;
99
:
14524
–9.
109
Lee M, Hyun D, Halliwell B, Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult.
J Neurochem
 
2001
;
76
:
998
–1009.
110
Gu M, Cooper JM, Taanman JW, Schapira AHV. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease.
Ann Neurol
 
1998
;
44
:
177
–86.
111
Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease.
Ann Neurol
 
1996
;
40
:
663
–71.
112
Hyun DH, Lee M, Hattori N, et al. Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome.
J Biol Chem
 
2002
;
277
:
28572
–7.
113
Lee MH, Hyun DH, Jenner P, Haliwell B. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production.
J Neurochem
 
2001
;
78
:
32
–41.
114
Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowerc M, Przedborski S. α –Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
J Neurochem
 
2000
;
74
:
721
–9.
115
Williams AC. Ecogenetics, xenobiotic biochemistry and neurological disease.
J Neurol
 
1991
;
238
:
187
–90.
116
Williams AC. Hypersusceptibility to chemicals: risk factors for neurological disease?
J Neurol Neurosurg Psychiat
 
1993
;
56
:
943
–6.
117
Williams AC. In:
Susceptibility to Neurotoxins in Neurodegenerative Diseases
 . Calne DB, ed. Saunders, 1993.
118
Naoi M, Maruyama W, Dostert P, Hashizume Y. N-methyl-(R)-salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease.
J Neural Transm
 
1997
;
50(Suppl.)
:
89
–105.
119
Spillane JD. Nutritional disorders of the nervous systems. In:
Pellagra
 , Chap 2. Edinburgh, E & S Livingstone,
1947
:
29
–47.
120
Deutch AY, Rosin DL, Goldstein M, Roth RH. 3-Acetyl pyridine-induced degeneration of the nigrostriatal dopamine system: an animal model of olivopontocerebellar atrophy-associated parkinsonism.
Exp Neurol
 
1989
;
105
:
1
–12.
121
Waring RH, Sturman SG, Smith MCG, Steventon GB, Heafield MTE, Williams AC. S-methylation in Motorneuron disease and Parkinson's disease.
Lancet
 
1989
;
ii
:
356
–7.
122
Peters L, Steventon GB, Green S, Sturman S, Waring RH, Williams AC. D-Penicillamine metabolism in neurodegenerative diseases: an in vivo/in vitro sulphydryl methylation study.
Xenobiotica
 
1994
;
24
:
1013
–20.
123
Kamel F, Umbach DM, Munsat TL, et al. Lead exposure and amyotrophic lateral sclerosis.
Epidemiology
 
2002
;
13
:
311
–19.
124
Pall HS, Williams AC, Waring R, Elias E. Motorneurone disease as manifestation of pesticide toxicity.
Lancet
 
1987
;
ii
:
685
.
125
Steventon GB, Waring RH, Williams AC. Pesticide toxicity and motor neuron disease.
J Neurol Neurosurg Psychiat
 
1990
;
53
:
621
–2.
126
Roth GS, Ingram DK, Lane MA. Caloric restriction in primates and relevance to humans.
Ann NY Acad Sci
 
2001
;
928
:
305
–15.

Author notes

From the Divisions of 1Neurosciences and 2Medical Sciences, University of Birmingham, Birmingham, UK